In 2013, the [[Food and Drug Administration]] required manufacturers to decrease the recommended dose for women by half, after studies showed that the medicines can leave people drowsy in the morning and at risk for [[motor vehicle collision]]s. The FDA recommended that manufacturers extend the new dosage cuts to men as well, who process the drug at a faster rate; however, the reasons men and women metabolize the drugs at different rates are still unknown.<ref>{{cite news | title = FDA tells drugmakers to lower doses for Ambien, other sleeping pills | url = http://www.cbsnews.com/8301-204_162-57563277/fda-tells-drugmakers-to-lower-doses-for-ambien-other-sleeping-pills/ | publisher = CBS News | accessdate = 10 January 2013}}</ref> In May 2013, the FDA approved label changes specifying new dosage recommendations for zolpidem products because of concerns regarding next-morning impairment.<ref>{{cite web | url = http://www.lawyersandsettlements.com/articles/personal_injury/Ambien-FDA-Dosing-changes-18721.html#.UZPs8St35cI | title = FDA Changes Dosing on Ambien, Ambien CR, Zolpidem and Edluar | publisher = Lawyersandsettlements.com | date = 2013-05-15 | accessdate = 2014-01-31}}</ref> The underlying mechanism involves [[Gamma-Aminobutyric acid|GABA]].

 

